In a surprising turn of events, GSK has announced that Emma Walmsley will step down as CEO at the end of the year, to be succeeded by Luke Miels. This move comes as the company works to strengthen its pipeline amid US trade tensions. Walmsley, the UK's most senior female CEO, led GSK through its consumer healthcare business spin-off but faced investor concerns about a reducing pipeline.

AstraZeneca, a leading Anglo-Swedish pharmaceutical firm, intends to switch to a direct U.S. listing to capitalize on the growing American stock market while affirming its commitment to remain UK-based. British investors, concerned about a potential UK exit, were reassured by the company's decision to maintain its listing in London.

In the world of biotechnology, Australian company CSL has announced that

See Full Page